Stay updated on Adagrasib Combo in KRAS G12C Clinical Trial
Sign up to get notified when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.

Latest updates to the Adagrasib Combo in KRAS G12C Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedNew recruitment locations and site contacts have been added (e.g., Teresa Garcia Manrique in Seville; Saitama Medical University International Medical Center; Gleneagles Penang), expanding the study's recruitment footprint. The total number of locations is updated to 767.SummaryDifference0.2%

- Check17 days agoChange DetectedThe page revision tag was updated to Revision: v3.5.4, replacing the previous v3.5.3. This indicates the page version was updated, likely including minor edits or fixes without changing the study details.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedNew study locations were added: Liuzhou, Guangxi, China (545006) and Taoyuan, Taiwan (333); Liuchow, Guangxi, China (545006) and Taoyuan District, Taiwan (333) were removed. The page revision updated to v3.5.3.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check59 days agoChange DetectedUpdated the study location listing from Padua, Italy 35128 to Padova, Italy 35128.SummaryDifference0.0%

- Check74 days agoChange DetectedAdded new trial locations and local institutions (e.g., Florianópolis, Salvador, Viedma) with investigator contacts, and removed several existing sites; total locations updated to 764.SummaryDifference0.2%

Stay in the know with updates to Adagrasib Combo in KRAS G12C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.